<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074423</url>
  </required_header>
  <id_info>
    <org_study_id>12-026</org_study_id>
    <nct_id>NCT02074423</nct_id>
  </id_info>
  <brief_title>A Human Clinical Trial Evaluating the Effect of MealShape™ on Blood Glucose Level Following Consumption of Standard Meal</brief_title>
  <official_title>A Randomized, Controlled, Double-blind, Cross-over Clinical Trial, Evaluating the Effect of MealShape™ on the Postprandial Glycemia After Eating Standard Food, in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dialpha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dialpha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of MealShape, a Ceylon cinnamon extract
      (Cinnamomum zeylanicum) on blood glucose and insulin response after consumption of a standard
      meal composed of white bread, in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose incremental Area Under the Curve between 0 and 120 minutes after consumption of a standard meal, compared between MealShape and the placebo</measure>
    <time_frame>Over 120 minutes after the consumption of a standard meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glucose incremental Area Under the Curve between 0 and 60 minutes compared between MealShape and the placebo after consumption of a standard meal,</measure>
    <time_frame>Over 60 minutes after consumption of a standard meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capillary blood glucose maximal concentration between MealShape and Placebo after consumption of a standard meal</measure>
    <time_frame>Over 120 minutes after consumption of a standard meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of glycemia values between MealShape and Placebo at the following time points: T0, T15, T30, T45, T60, T90 and T120 minutes after consumption of a standard meal</measure>
    <time_frame>Over 120 minutes after consumption of a standard meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety of MealShape with adverse events recording</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin incremental Area under the Curve between 0 and 120 minutes compared between MealShape and Placebo after consumption of a standard meal</measure>
    <time_frame>Over 120 minutes after consumption of a standard meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin incremental Area under the Curve between 0 and 60 minutes compared between MealShape and Placebo after consumption of a standard meal</measure>
    <time_frame>Over 60 minutes after connsumption of a standard meal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Postprandial Glycemia</condition>
  <condition>Postprandial Insulinemia</condition>
  <arm_group>
    <arm_group_label>MealShape cinnamon extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MealShape cinnamon extract</intervention_name>
    <description>Acute administration of 1 g PO (2 capsules of 500 mg)</description>
    <arm_group_label>MealShape cinnamon extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute administration of 1 g PO (2 capsules of 500 mg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers, able to read and write, aged from 18 to 45 years
             inclusive at time of screening

          -  Good physical condition

          -  Body Mass Index (BMI) ≥ 18,5 and &lt; 25 kg/m²

          -  Written informed consent provided prior to screening, after receiving and
             understanding the subject information

          -  Stable body weight (&lt; 5% variation) within the last 3 months prior to screening.

          -  Subject accepting to keep the same lifestyle throughout the study regarding physical
             activity, no smoking etc.

          -  Registered with the French Social Security, in agreement with the French law on
             biomedical experimentation.

        Exclusion Criteria:

          -  Subject with type 1 or 2 diabetes

          -  Smoker. Light smoker (less than 5 cigarettes per day) or former smoker (smoking more
             than 5 cigarettes per day) having stopped less than three months. Smoking (or use of
             smoking substitute e.g. nicotine patch) is not permitted from screening throughout the
             study.

          -  Subject with fasting capillary blood glucose level &gt; 110 mg/dl.

          -  Subject with fasting capillary blood glucose level ≤ 110 mg/dl and 2 hours
             postprandial capillary blood glucose level &gt; 140 mg/dl during an Oral Glucose
             Tolerance Test.

          -  Subject with any sensitivity or allergy to any of the products used within this
             clinical trial.

          -  Intake of product (food and dietary supplement) having an effect on glycemia and
             insulinemia.

          -  Intake of all chronic medication excepted oestroprogestative or progestative
             contraception started at least three months preceding the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Deplanque</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naturalpha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Nutrition Clinique Naturalpha</name>
      <address>
        <city>Lilles</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.efsa.europa.eu/fr/efsajournal/doc/2604.pdf</url>
    <description>Guidance on the scientific requirements for health claims related to 2 appetite ratings, weight management, and blood glucose concentrations</description>
  </link>
  <link>
    <url>http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf</url>
    <description>World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : report of a WHO/IDF consultation</description>
  </link>
  <reference>
    <citation>Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001 Dec 13;414(6865):782-7. Review.</citation>
    <PMID>11742409</PMID>
  </reference>
  <reference>
    <citation>Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz W. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012 Jun;42(6):563-70. doi: 10.1016/j.amepre.2011.10.026.</citation>
    <PMID>22608371</PMID>
  </reference>
  <reference>
    <citation>Rafehi H, Ververis K, Karagiannis TC. Controversies surrounding the clinical potential of cinnamon for the management of diabetes. Diabetes Obes Metab. 2012 Jun;14(6):493-9. doi: 10.1111/j.1463-1326.2011.01538.x. Epub 2011 Dec 27. Review.</citation>
    <PMID>22093965</PMID>
  </reference>
  <reference>
    <citation>Davis PA, Yokoyama W. Cinnamon intake lowers fasting blood glucose: meta-analysis. J Med Food. 2011 Sep;14(9):884-9. doi: 10.1089/jmf.2010.0180. Epub 2011 Apr 11. Review.</citation>
    <PMID>21480806</PMID>
  </reference>
  <reference>
    <citation>Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008 Jan;31(1):41-3. Epub 2007 Oct 1.</citation>
    <PMID>17909085</PMID>
  </reference>
  <reference>
    <citation>Magistrelli A, Chezem JC. Effect of ground cinnamon on postprandial blood glucose concentration in normal-weight and obese adults. J Acad Nutr Diet. 2012 Nov;112(11):1806-9. doi: 10.1016/j.jand.2012.07.037.</citation>
    <PMID>23102179</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cinnamon extract</keyword>
  <keyword>Postprandial glycemia</keyword>
  <keyword>Glycemic index</keyword>
  <keyword>Pre-diabetes</keyword>
  <keyword>Metabolic syndrome</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

